TY - JOUR
T1 - Incidence of central serous chorioretinopathy (2011-2018)
T2 - a nationwide population-based cohort study of Japan
AU - Kido, Ai
AU - Miyake, Masahiro
AU - Tamura, Hiroshi
AU - Hiragi, Shusuke
AU - Kimura, Takeshi
AU - Ohtera, Shosuke
AU - Takahashi, Ayako
AU - Ooto, Sotaro
AU - Kawakami, Koji
AU - Kuroda, Tomohiro
AU - Tsujikawa, Akitaka
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/7/14
Y1 - 2021/7/14
N2 - Aims The aim of this study was to elucidate the epidemiological background of central serous chorioretinopathy (CSC), including its incidence and treatment pattern. Methods This was a population-based longitudinal cohort study using a nationwide health insurance claims database of the Japan Ministry of Health, Labour and Welfare (MHLW). As Japan employs universal health coverage, the database covers more than 95% of claims issued in Japan. We accessed all data stored in the database with permission from the MHLW. We traced all individuals aged 30 years or older and identified individuals with new onset of CSC between January 2011 and December 2018. CSC cases were categorised by age and sex for each year, and incidence rate was calculated. We also identified major treatments for CSC to elucidate the initial treatment pattern. Results During the 8-year period, 247 930 incidences of CSC were identified, among which 75.9% were men. The crude incidence rate (per 100 000 person-years) in the general population aged 30 years or older was 34.0 (95% CI 33.9 to 34.2), in men was 54.2 (95% CI 53.9 to 54.4) and in women was 15.7 (95% CI 15.5 to 15.8). The mean age of onset was lower in men than in women (50.5±12.5 years vs 54.7±13.5 years). Most of the patients with newly diagnosed CSC (86.8%) did not receive major treatment. Conclusions The current study provides the nationwide population-based evidence to clarify the detailed epidemiology of CSC. These results could help to understand the pathogenesis and mechanisms of CSC in the future.
AB - Aims The aim of this study was to elucidate the epidemiological background of central serous chorioretinopathy (CSC), including its incidence and treatment pattern. Methods This was a population-based longitudinal cohort study using a nationwide health insurance claims database of the Japan Ministry of Health, Labour and Welfare (MHLW). As Japan employs universal health coverage, the database covers more than 95% of claims issued in Japan. We accessed all data stored in the database with permission from the MHLW. We traced all individuals aged 30 years or older and identified individuals with new onset of CSC between January 2011 and December 2018. CSC cases were categorised by age and sex for each year, and incidence rate was calculated. We also identified major treatments for CSC to elucidate the initial treatment pattern. Results During the 8-year period, 247 930 incidences of CSC were identified, among which 75.9% were men. The crude incidence rate (per 100 000 person-years) in the general population aged 30 years or older was 34.0 (95% CI 33.9 to 34.2), in men was 54.2 (95% CI 53.9 to 54.4) and in women was 15.7 (95% CI 15.5 to 15.8). The mean age of onset was lower in men than in women (50.5±12.5 years vs 54.7±13.5 years). Most of the patients with newly diagnosed CSC (86.8%) did not receive major treatment. Conclusions The current study provides the nationwide population-based evidence to clarify the detailed epidemiology of CSC. These results could help to understand the pathogenesis and mechanisms of CSC in the future.
UR - http://www.scopus.com/inward/record.url?scp=85142918963&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142918963&partnerID=8YFLogxK
U2 - 10.1136/bjophthalmol-2021-319403
DO - 10.1136/bjophthalmol-2021-319403
M3 - Article
C2 - 34261662
AN - SCOPUS:85142918963
SN - 0007-1161
VL - 106
SP - 1748
EP - 1753
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 12
ER -